Shire To Announce Second Quarter 2017 Results
Shire to announce second quarter 2017 results
Dublin, Ireland - July 18, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), will announce second quarter 2017 earnings on Thursday August 3, 2017.
| Results press release will be issued at: | 12:00 BST / 07:00 EDT |
| Investor conference call time: | 14:00 BST / 09:00 EDT |
Live conference call for investors:
Flemming Ornskov, MD, Chief Executive Officer and Jeff Poulton, Chief Financial Officer will host the investor and analyst conference call at 9:00 EDT / 14:00 BST.
The details of the conference call are as follows:
| UK dial in: | 0808 237 0030 or 020 3139 4830 |
| US dial in: | 1 866 928 7517 or 1 718 873 9077 |
| International Access Numbers: | http://events.arkadin.com/ev/docs/NE_FEL_Events_International_Access_List.pdf |
| Password/Conf ID: | 96350792# |
| Live Webcast: | http://investors.shire.com/presentations-and-reports/quarterly-results-and-presentations |
Replay:
A replay of the presentation will be available for two weeks by phone and by webcast for three months. Replay information can be found on the Investor Relations section of Shire's website at http://investors.shire.com/.
For further information please contact:
| Investor Relations | ||
| Ian Karp | ikarp@shire.com | +1 781 482 9018 |
| Robert Coates | rcoates@shire.com | +44 1256 894874 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.